**Specifications table**Subject area*Biomedicine*More specific subject area*Quantitative proteomics, sleeping sickness, clinical biomarkers*Type of data*Table of proteins significantly differentially expressed* (*obtained with Isobar*); *list of all protein identifications and quantifications* (*Excel file, Supplementary MS data*)How data was acquired*NSI-LTQ Orbitrap Velos* (*Thermo Electron*)Data format*MS/MS data analysed for identification and quantification*Experimental factors*CSF samples were submitted to the modified single centrifugation sample preparation for sleeping sickness diagnostic purposes, as described by Miezan et al.*[@bib1]. *For each patients, 60 µL of CSF was used for the proteomics sample preparation.*Experimental features*CSF samples were analysed by quantitative proteomics. Proteins were digested with trypsin and labelled with the TMT 6-plex reagents. The pooled labelled sample was subjected to off-gel electrophoresis (OGE) fractionation* (*12 fractions*) *prior to LC--MS/MS analysis of each individual fraction.*Data source locationS*amples were collected in the Democratic Republic of the Congo and in Uganda. All the analyses* (*quantitative proteomics, data analysis*) *have been performed in Geneva* (*Switzerland*).Data accessibility*Data are publicly available via ProteomeXchange and can be accessed through the identifier PXD001082* (<http://www.ebi.ac.uk/pride/archive/projects/PXD001082>)

1. Value of the data {#s0005}
====================

•The TMT quantitative approach is a powerful tool to characterise and compare CSF proteome.•The combination of proteomic and bioinformatics is useful to understand HAT pathophysiology.•Quantitative proteomic showed that *T. b. rhodesiense* strongly evokes innate immunity activation.

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Experimental design {#s0015}
------------------------

In the present work we investigated the cerebrospinal fluid (CSF) from *T. b. gambiense* (*n*=3) and *T. b. rhodesiense* (*n*=3) HAT patients using TMT quantitative proteomics. The quantitative analyses, performed on the identified proteins, highlighted proteins differentially expressed between the two forms of HAT. The proteomics data here presented, are part of a larger investigation on the biological mechanisms and pathways specifically associated to the *rhodesiense* form of HAT when compared to the *gambiense* one, published in 2015 [@bib2]. The complete experimental design involving the proteomics investigations here reported is represented in [Fig. 1](#f0005){ref-type="fig"}.

2.2. Patients and ethical statement {#s0020}
-----------------------------------

HAT patients investigated by quantitative proteomics were enrolled in the Democratic Republic of the Congo (D.R.C.) and in Uganda, as part of prospective studies already published elsewhere [@bib3; @bib4]. The relevant Institutional and National Ethics Committees of the D.R.C., Uganda and Belgium approved the respective studies. All participants signed a written informed consent, accepted to be enrolled in the studies and had the possibility to withdraw at any moment.

Patients were diagnosed and staged for sleeping sickness according to the guidelines of the national sleeping sickness control programs of the country of sample collection. For the present study, patients were classified as stage 2 (i.e., presence of parasites in CSF and/or CSF WBC count \>5 cells/µl) following WHO guidelines [@bib5].

CSF was collected to determine HAT stage and was subjected to the modified single centrifugation for parasite detection [@bib1]. Our proteomics analyses were performed on the supernatant of this centrifugation. All CSF samples here investigated were collected before treatment administration.

2.3. Proteomics {#s0025}
---------------

### 2.3.1. Samples {#s0030}

CSF samples (*n*=6) obtained from 6 HAT patients were investigated. Among them, 3 patients suffered from S2 *T. b. gambiense* HAT and originated from the D.R.C. [@bib3] and 3 patients suffered from S2 *T. b. rhodesiense* and originated from endemic regions in Uganda -- Serere district (FINDTRYP study) [@bib4]. The demographic description of the patients is reported in [Table 1](#t0005){ref-type="table"}.

### 2.3.2. Sample preparation and peptide labelling {#s0035}

For each sample, 60 µL of CSF was used. An internal control was spiked in each sample (0.5 µg of bovine beta-lactoglobulin, SigmaAldrich). Proteins were then reduced with 50 mM *tris*(2-carboxyethyl)phosphine (TCEP) and alkylated with 400 mM iodoacetamide, prior to digestion into peptides with trypsin 0.2 µg/µL (Promega).

Digested samples were labelled with the TMT^®^ 6-plex tagging reagents (Thermo Fisher Scientific) following manufacturer׳s instructions. *T. b. gambiense* samples were labelled with the tags TMT-126, TMT-127 and TMT-128, while *T. b. rhodesiense* samples were labelled with the tags TMT-129, TMT-130 and TMT-131 ([Table 1](#t0005){ref-type="table"}). After tagging, the 6 samples were pooled, dried under vacuum and desalted with C18 Macro Spin Columns (Harvard Apparatus).

The pooled sample was then fractionated by off-gel electrophoresis (OGE -- Agilent) into 12 fractions using a 13 cm, pH 3--10 linear IPG strip (GE Healthcare). Each OGE fraction was desalted with C18 Micro Spin Columns (Harvard Apparatus), dried under vacuum and analysed by tandem mass spectrometry [@bib6; @bib7].

### 2.3.3. Mass spectrometry analyses {#s0040}

MS analyses were performed on a nanoelectrospray ionisation (NSI) LTQ Orbitrap (OT) velos from Thermo Electron equipped with a NanoAcquity system from Waters. Peptides were trapped on a home-made 5 µm 200 Å Magic C18 AQ (Michrom) 0.1×20 mm^2^ pre-column and separated on a home-made 5 µm 100 Å Magic C18 AQ (Michrom) 0.75×150 mm^2^ column with a gravity-pulled emitter. A gradient of 65 min was applied for the analytical separation using H~2~O/formic acid (FA) 99.9%/0.1% as solvent A and CH~3~CN/FA 99.9%/0.1% as solvent B. The gradient was run at a flow rate of 220 nL/min as follows: 0--1 min 5% B, to 35% B at 55 min and then to 80% B at 65 min.

For MS survey scans, the OT resolution was set to 60,000 and the ion population was set to 5×10^5^ with an *m/z* window from 400 to 2000. A maximum of 3 precursors were selected for both collision-induced dissociation (CID) in the LTQ and higher energy collision dissociation (HCD) with analysis in the OT. For MS/MS in the LTQ, the ion population was set to 7000 (isolation width of 2 *m/z*) while for MS/MS detection in the OT, it was set to 2×10^5^ (isolation width of 2.5 *m/z*), with resolution of 7500, first mass at *m/z*=100 and maximum injection time of 750 ms. The normalised collision energies were set to 35% for CID and 60% for HCD [@bib7].

### 2.3.4. Protein identification and quantification {#s0045}

Protein identification was obtained with the EasyProt platform v2.3 [@bib8]. After peak list generation using ReadW software, CID and HCD spectra were merged to obtain the simultaneous identification and quantification [@bib7].

Proteins were identified by searching peptide spectral matches against the Swiss-Prot/UniProt database (Version 13-June-2012, 536′489 entries) choosing the *Homo sapiens* taxonomy. For EasyProt protein search, carbamidomethylation of cysteines, TMT six-plex amino-termini and TMT six-plex lysines were set as fixed modifications, while oxidised methionines as variable. Trypsin was selected as the digestion enzyme with only 1 missed-cleavage allowed, only peptides with a minimum of 6 residues were selected for identification and the precursor ion tolerance was set to 10 ppm.

The efficient technical performance of the experiment was evaluated through the peptide labelling rate (over 93%) and the technical variability through the peptide relative intensity distribution of the bovine beta-lactoglobulin among the 6 channels (CV\<17%).

Only proteins identified with at least 2 unique peptides and with an FDR≤1% (computed at the PSM level) were considered for further quantitative analyses using Isobar quantification tool (version 1.76) [@bib9], embedded in EasyProt. Only peptides specific for a unique entry in the job were taken into account for protein quantification. The isotopic purity correction (according to the algorithm given by the manufacturer) of each channel and the Isobar default normalisation [@bib9] were applied. Finally, the protein ratio *T. b. rhodesiense*/*T. b. gambiense* was computed according to the tagging design, i.e. TMT129+130+131/TMT126+127+128 and the ratio and sample *p*-Values were calculated by the software [@bib9]. Proteins having both ratio *p*-Value (estimator of ratio accuracy relative to the quality of the spectra) and sample *p*-Value (estimator of the biological variability) significant were considered as differentially expressed. The list of proteins significantly differentially expressed is reported in [Table 2](#t0010){ref-type="table"}.

The mass spectrometry raw data were deposited into the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) [@bib10] via the PRIDE partner repository [@bib11] with the dataset identifier PXD001082.

The list of identified (*n*=239) and quantified (*n*=222) proteins, with the respective protein ratio and statistics is reported in Supplementary MS data ([Tables S1 and S2](#s0065){ref-type="sec"}).

### 2.3.5. Gene ontology and pathway analyses {#s0050}

The experimental protein dataset was then evaluated in the context of HAT pathophysiology. To point out specific mechanisms significantly associated to one of the two forms of sleeping sickness, quantified proteins and proteins significantly differentially expressed were submitted to pathway (IPA Ingenuity) and gene ontology (GO -- BioCompendium) analyses, respectively.
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![Graphical representation of the complete experimental design of the study involving the TMT 6-plex experiment and dataset described.](gr1){#f0005}

###### 

Demographic description of patients investigated in the TMT 6-plex experiment.

                              *T. b. gambiense* - D.R.C.   *T. b. rhodesiense* - UGANDA                                                                                    
  --------------------------- ---------------------------- ------------------------------ -------------------------- -------------------------- -------------------------- --------------------------
                              **[Pt \#1]{.smallcaps}**     **[Pt \#2]{.smallcaps}**       **[Pt \#3]{.smallcaps}**   **[Pt \#4]{.smallcaps}**   **[Pt \#5]{.smallcaps}**   **[Pt \#6]{.smallcaps}**
                                                                                                                                                                           
  Sex                         F                            F                              F                          F                          F                          F
  Age                         21                           29                             51                         22                         30                         53
  [T+CSF]{.smallcaps}         Yes                          Yes                            Yes                        Yes                        Yes                        Yes
  [WBC/µL]{.smallcaps}        135                          217                            97                         119                        231                        70
  **[TMT tag]{.smallcaps}**   **126**                      **127**                        **128**                    **129**                    **130**                    **131**

T+ CSF: presence of parasites in the CSF, WBC/µL: number of leucocytes/µL of CSF.

###### 

List of proteins significantly differentially expressed between *rhodesiense* and *gambiense* S2 CSF. Only proteins identified with at least 2 unique peptides and FDR\<1% were considered for quantification.

  **\#**   **AC**   **Protein**                                    **Gene**   **Peptide count**   **Spectral count**   **Ratio**[⁎](#tbl2fnStar){ref-type="table-fn"}   *p* Value ratio   ***p*****Value sample**
  -------- -------- ---------------------------------------------- ---------- ------------------- -------------------- ------------------------------------------------ ----------------- -------------------------
  1        P06311   Ig kappa chain V--III region IARC/BL41         Na         2                   2                    0.69                                             0.007             0.002
  2        O00584   Ribonuclease T2                                RNASET2    3                   3                    0.69                                             0.006             0.019
  3        Q9NPR2   Semaphorin-4B                                  SEMA4B     2                   2                    0.72                                             0.048             0.017
  4        P04114   Apolipoprotein B-100                           APOB       4                   5                    1.36                                             0.041             0.045
  5        P19652   Alpha-1-acid glycoprotein 2                    ORM2       5                   10                   1.49                                             0.005             0.017
  6        Q03591   Complement factor H-related protein 1          CFHR1      1                   1                    1.52                                             0.023             0.036
  7        P02748   Complement component C9                        C9         8                   10                   1.78                                             0.006             0.003
  8        Q14624   Inter-alpha-trypsin inhibitor heavy chain H4   ITIH4      10                  18                   1.80                                             0.005             0.026
  9        P18428   Lipopolysaccharide-binding protein             LBP        2                   2                    2.31                                             0.046             0.000
  10       P02763   Alpha-1-acid glycoprotein 1                    ORM1       6                   28                   2.69                                             0.001             0.000
  11       P02741   C-reactive protein                             CRP        3                   5                    9.30                                             0.001             0.000

Peptide count and spectral count correspond to the number of peptides and of spectra used for the quantification, respectively.

*T. b. rhodesiense*/*T. b. gambiense* \[129+130+131/126+127+128\].

[^1]: Present address: Vascular Immunology Unit, Department of Pathology, Sydney Medical School, The University of Sydney, Sydney, Australia.
